Sign In
Buy AMRN
$14.53
+0.0600 (+0.415%)
At Close: Jun 03, 2026
Amarin Receives European Commission (EC) Approval for VAZKEPA to Reduce Cardiovascular Risk
06:24am, Tuesday, 30'th Mar 2021
Marks first and only EC-approved treatment to reduce cardiovascular risk in high-risk, statin-treated adult patients who have elevated triglycerides (≥150 mg/dL) and other risk characteristics as st
10 Cheap Stocks Under $10 That Don't Deserve Your Time or Money
11:12am, Tuesday, 23'rd Mar 2021
There are plenty of cheap stocks out there, but don't confuse inexpensive for undervalued; these 10 stocks under $10 should be avoided. The post 10 Cheap Stocks Under $10 That Don't Deserve Your Time
Amarin's Vascepa Associated With Stroke Reduction
02:18pm, Wednesday, 17'th Mar 2021
Amarin Corporation plc (NASDAQ: AMRN) has announced new prespecified and post hoc analyses from the REDUCE-IT study, evaluating Vascepa (icosapent ethyl). Data were presented at International Stro
28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, witho
Amarin Corporation plc (AMRN) CEO John Thero Presents at Cowen 41st Annual Health Care Conference (Transcript)
02:40pm, Monday, 01'st Mar 2021
Amarin Corporation plc (AMRN) CEO John Thero Presents at Cowen 41st Annual Health Care Conference (Transcript)
Amarin (AMRN) Q4 Earnings & Revenues Top, Vascepa Sales Solid
10:37am, Friday, 26'th Feb 2021
Amarin's (AMRN) revenue growth in the fourth quarter is attributable to continued demand for its cardiovascular drug, Vascepa.
Amarin Corporation plc's (AMRN) CEO John Thero on Q4 2020 Results - Earnings Call Transcript
02:16pm, Thursday, 25'th Feb 2021
Amarin Corporation plc's (AMRN) CEO John Thero on Q4 2020 Results - Earnings Call Transcript
How Amarin Beat Wall Street's Q4 Estimates
11:21am, Thursday, 25'th Feb 2021
The drugmaker topped analysts' top- and bottom-line expectations despite challenges from a generic rival and the pandemic.
Amarin Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
05:55am, Thursday, 25'th Feb 2021
Record Revenue of $614.1 Million and $167.3 Million for Full Year and Fourth Quarter 2020 Despite COVID-19 Impact
8 Sleeper Stocks That Could Take Off Soon
09:05am, Monday, 22'nd Feb 2021
With the crazy bullishness in the market, you can't find too many discounted plays. However, these sleeper stocks might just give your portfolio the kickstart it needs in 2021.
Amarin to Present at Two Upcoming Investor Conferences
06:05am, Thursday, 18'th Feb 2021
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is sch
Amarin to Report Fourth Quarter and Full Year 2020 Results and Host Conference Call on February 25, 2021
08:05am, Wednesday, 17'th Feb 2021
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior manageme
10 Hot Stocks to Buy That Ought to Stay Hot in 2021
09:19am, Wednesday, 10'th Feb 2021
If you're looking for hot stocks to buy, it makes sense to focus your search on growth companies. Here are 10 picks that ought to stay hot.
Why Amarin Rose as Much as 7.9% Today
07:00pm, Tuesday, 09'th Feb 2021
The approval process for its top drug is starting in two major Asian markets.
Amarin Provides Update on VASCEPA® (Icosapent Ethyl) Regulatory Review Processes in Mainland China and Hong Kong
07:00am, Tuesday, 09'th Feb 2021
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that its corporate partner in China, Edding, has progressed VASCEPA® (ico
